Dynamic precision medicine enables preemptive cancer therapy switching in response to emerging resistance. Owing to their modular architecture and tumour-targeting capabilities, nanomedicines are theoretically well-suited to support such adaptive strategies. However, the questions remain whether modular design can consistently yield durable therapeutic responses, and whether the temporal constraints imposed by tumour evolution allow the practical implementation of dynamic nanomedicine.
- Alexandre Detappe
- Fabrice André
